To evaluate the histologic effects of tamoxifen on the endometrium using hysteroscopy in postmenopausal women with breast cancer. Methods: The study included 46 postmenopausal patients who were referred from another clinic due to thickening or bleeding of the endometrium after taking tamoxifen for breast cancer. All patients underwent transvaginal sonography (TVS) and hysteroscopic endometrial biopsy with a 5-mm, continuous-flow, operating hysteroscope. Results: The incidence of malignancy was high (20%) in cases of abnormal uterine bleeding (AUB) after taking tamoxifen. However, in the non-AUB group with thick endometrium after taking tamoxifen, the incidence of adenocarcinoma was 3.2%. Conclusions: Our findings confirm the estrogen-like effect of tamoxifen on the endometrium. Endometrial evaluation with TVS suggests further diagnostic procedures; moreover, histologic examination is necessary under hysteroscopy, especially in cases of endometrial bleeding after taking tamoxifen. (J Menopausal Med 2018;24:81-86)
Introduction
Tamoxifen has been used as adjuvant therapy for breast cancer in postmenopausal women, but has been implicated in endometrial changes. Therefore, gynecologic surveillance of asymptomatic women is needed. 1 Endometrial pathology has been identified in up to 35.5% of postmenopausal breast cancer tamoxifen-treated patients. 2 Benign endometrial polyps are the most common pathology described in these patients, with an incidence of 8% to 36%. 3 Some women develop recurrent polyps with an incidence of malignancy of up to 10.7%. 4 There is therefore an urgent need for a long-term investigation on the incidence of endometrial pathologies among large cohorts of postmenopausal breast cancer patients following continuous tamoxifen therapy for 5 years.
Because of the estrogenic effects on the endometrium, it is necessary to screen postmenopausal patients taking tamoxifen, especially those with no gynecologic symptoms. 5 Transvaginal sonography (TVS) is considered a simple, Hysteroscopy directly visualizes the endometrium and allows biopsy tissue to be precisely sampled. 5 We performed hysteroscopy to evaluate the effect of prolonged tamoxifen therapy on endometrium of postmenopausal patients with breast cancer. In asymptomatic women, endometrial thickness on TVS was the indication for hysteroscopy.
Materials and Methods
We One of the 3 suspicious adenocarcinomas was found to be atypical hyperplasia on histologic examination (Table 2) .
When the 2 groups were compared, the incidence of malignancy was high in cases with bleeding. However, more research is needed because of the small sample size.
Hysteroscopy had a sensitivity of 0.85, specificity of 0.83, positive predictive value of 0.79, and negative predictive value of 0.87. A significant difference was found between the presence or absence of endometrial pathology and dura- 
Nonspecific endometrium refers to all cases in which no pathologic lesions are seen 
tion of tamoxifen therapy (in months; P < 0.05), with longer therapy associated with more pathologic findings on histology (Table 3) .
Discussion
Tamoxifen is a nonsteroidal selective estrogen receptor modulator that is used primarily for adjuvant treatment of estrogen receptor-positive breast cancer in premenopausal women, and in some postmenopausal women. 9 It is also used for chemoprevention in women at increased risk of breast cancer. Tamoxifen is associated with increased risks of uterine pathology, including endometrial polyps, endometrial carcinoma, hyperplasia, uterine sarcoma, and uterine carcinosarcoma.
Ozşener et al. 10 showed that tamoxifen use increases the risk of endometrial cancer and premalignant change. They also noted a significant association between endometrial thickness and duration of tamoxifen treatment (P = 0.025).
Hann et al. 11 reported abnormal endometrial biopsies in 44% of women treated with tamoxifen for less than 5 years, whereas 58% of endometrial biopsies revealed abnormal results when duration of tamoxifen treatment was > 5 years.
Cohen et al. 12 showed that 28.6% of patients on tamoxifen had endometrial pathology. The incidence was significantly more in symptomatic patients. Seoud et al. 13 concluded that the value of routine screening for endometrial pathology in patients on tamoxifen is controversial. They found that all patients who developed an abnormal endometrium had abnormal vaginal bleeding.
Clinical trials confirm that long-term tamoxifen therapy for breast cancer for at least 5 years, is more effective than short-term treatment (< 2 years). 3, 14 During that time, tamoxifen acts on the endometrium as an estrogen receptor agonist. Its effects vary depending on dosage, duration of treatment, and patient age and menopausal status. 15 The frequency of endometrial cancer was reported to dou- 
